US Patent 8,231,885: Brimonidine and Titanium Dioxide Topical Composition Patent Analysis

US Patent 8,231,885 protects topical dermal formulations combining brimonidine, titanium dioxide, and specified pharmaceutical carriers. Its strongest commercial relevance is to brimonidine topical gels and creams for facial, non-ophthalmic use, including the formulation architecture associated with Mirvaso. The patent does not broadly cover every topical brimonidine product. Titanium dioxide is a required element of every independent composition and container claim.

The patent’s principal commercial risk is formulation-based: a competing product containing brimonidine but omitting titanium dioxide would fall outside the literal scope of the issued claims, subject to any doctrine-of-equivalents analysis. Products using titanium dioxide in a qualifying topical carrier remain exposed through composition and container claims.

What does US Patent 8,231,885 cover?

US 8,231,885, titled “Topical compositions containing brimonidine,” was issued to Allergan, Inc. on July 31, 2012. The application was filed on November 10, 2010, and claims priority to an earlier filing. The patent covers formulations, dosage forms, and containers containing brimonidine or a pharmaceutically acceptable salt, titanium dioxide, and a topical carrier. [1]

The patent has four main claim groups:

Claim group	Claims	Protected subject matter
General topical compositions	1-16	Brimonidine, titanium dioxide, and topical carriers
Broader carrier and active-agent language	17	Brimonidine as the sole active agent, titanium dioxide, and expanded carrier list
Delivery containers	18-19	Containers holding the claimed formulation
Facial, non-ophthalmic compositions	20-22	Facial-use formulations and containers

The patent is formulation-focused. It does not claim a method of treating rosacea, facial erythema, or another disease in the claims identified by the user. It also does not claim brimonidine as a chemical compound.

What are the required elements of independent claims 1, 17, 18, 20, 21, and 22?

Each independent claim requires brimonidine and titanium dioxide. The following table identifies the principal limitations.

Claim	Required elements	Scope observation
1	Therapeutically effective brimonidine or salt; titanium dioxide; listed topical carrier; skin-suitable composition	Broad composition claim, but limited by titanium dioxide and listed carrier categories
17	Active agent consisting of brimonidine or salt; titanium dioxide; expanded carrier list	Adds ointments and unguents; “consisting of” narrows the active-agent identity
18	Container containing brimonidine, titanium dioxide, and listed carrier	Product-by-container claim; infringement can arise from the packaged formulation
20	Claim 1-type composition limited to facial and non-ophthalmic topical use	Directly aligned with facial erythema products
21	Claim 17-type composition limited to facial and non-ophthalmic use	Facial-use version with expanded carrier list
22	Container holding facial, non-ophthalmic formulation	Packaging claim tied to facial use

The “selected from the group consisting of” language generally indicates a closed Markush category for the carrier. The listed carrier must be a spray, mist, aerosol, lotion, gel, cream, paste, emulsion, or, for claim 17, ointment or unguent.

A formulation using an unlisted dosage form may avoid literal infringement of a claim with the narrower carrier list. The result depends on formulation characterization. A semisolid product marketed as a balm, for example, could still be treated as a cream, gel, ointment, paste, or emulsion depending on its physical properties and claim construction.

How do the dependent claims narrow the patent scope?

Claims 2 through 16 impose formulation-specific limitations. They create narrower fallback positions with practical relevance to commercial development.

Claims	Limitation
2, 5, 12	pH from about 5 to 8
3-9	Aqueous gel formulations
4, 11	Brimonidine concentration from about 0.01% to 5% by weight
6, 13	Preservative
7, 14	Local anesthetic
8, 15	Skin humectant
9	Water and a water-gelling amount of carbomer, glycerine polyacrylate, or mixtures
10-16	Cream formulations
16	Stearic acid, stearyl alcohol, cetyl alcohol, glycerin, and water

The most commercially important dependent claims are claims 4, 5, 9, 11, 12, and 16. They map onto standard dermatological formulation attributes:

Low-to-moderate brimonidine concentration.
Near-neutral pH.
Aqueous gel architecture.
Carbomer-based rheology.
Conventional oil-in-water cream components.

A product may infringe claim 1 even if it does not meet the narrower pH, concentration, preservative, humectant, or gelling-agent limitations. Dependent claims expand litigation leverage because a challenger must address multiple formulation permutations rather than a single broad claim.

What formulation is most exposed to US 8,231,885?

A brimonidine topical gel is most exposed when it includes:

Brimonidine or brimonidine tartrate.
Titanium dioxide.
Water.
Carbomer or another covered gelling agent.
A pH between approximately 5 and 8.
Brimonidine at approximately 0.01% to 5% by weight.
A tube or squeeze bottle.

That combination can implicate claims 1, 3, 4, 5, 9, 18, and 19. If the product is limited to facial and non-ophthalmic use, claims 20, 21, and 22 become particularly relevant.

The presence of titanium dioxide is decisive. Brimonidine alone is not enough. A formulation containing brimonidine, carbomer, glycerin, and water but no titanium dioxide would not satisfy the express titanium-dioxide limitation.

Does the patent cover Mirvaso?

Mirvaso is brimonidine tartrate topical gel, 0.33%, approved by the FDA for the topical treatment of persistent facial erythema associated with rosacea. The product is administered to the face and is not an ophthalmic formulation. [2]

The patent’s claim architecture corresponds closely to that product category:

Mirvaso-related characteristic	Relevance to US 8,231,885
Brimonidine tartrate	Satisfies brimonidine salt limitation
0.33% strength	Within the 0.01% to 5% dependent-claim range
Topical gel	Within claims 1, 3, 17, and related claims
Facial administration	Relevant to claims 20-22
Non-ophthalmic use	Expressly required by claims 20-22
Titanium dioxide	Required by every independent claim

The FDA-approved label identifies the active ingredient as brimonidine tartrate equivalent to brimonidine and describes topical facial administration. [2] The Orange Book should be used to confirm the patent listing and any current regulatory exclusivity associated with the approved product. [3]

When does US Patent 8,231,885 lose exclusivity?

The ordinary 20-year patent term is calculated from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and any corrected USPTO term data. Based on the November 10, 2010 nonprovisional filing date, the nominal term is expected to run to approximately November 10, 2030, unless the official USPTO or FDA listing reflects a different adjusted date. [1, 3]

The practical exclusivity date may differ from the nominal patent expiration because:

FDA Orange Book listings can include patent-specific use codes.
Patent-term adjustment can move expiration later.
A terminal disclaimer can shorten expiration.
Regulatory exclusivity may expire before the patent.
Litigation settlements can permit an earlier authorized generic or licensed launch.

The patent was issued in 2012 and remains within its ordinary term as of 2025. No biosimilar framework applies because brimonidine is a small-molecule active ingredient, not a biologic.

What is the Orange Book status of US 8,231,885?

US 8,231,885 is relevant to the Orange Book analysis for brimonidine tartrate topical gel products, particularly Mirvaso and its approved equivalents. Orange Book relevance depends on whether the patent is listed against the specific approved drug product and whether the listing carries a method-of-use code, formulation relevance, or both. [3]

For generic applicants, the principal regulatory question is whether an ANDA must address the patent with:

Paragraph I certification, if the patent is not listed as relevant;
Paragraph II certification, if the patent has expired;
Paragraph III certification, if the applicant will wait until expiration; or
Paragraph IV certification, if the applicant asserts that the patent is invalid, unenforceable, or not infringed.

Because US 8,231,885 contains formulation claims, a generic applicant would need to assess the formulation composition, excipient profile, labeling, packaging, and any proposed design-around. A Paragraph IV certification can trigger patent litigation if the NDA holder or patent owner brings suit within the statutory period. [4]

Which companies are likely to challenge or design around the patent?

The relevant competitive group includes:

Generic dermatology manufacturers seeking approval for brimonidine topical gel.
Companies developing alternative topical alpha-adrenergic formulations.
Contract manufacturers supplying private-label rosacea products.
Innovators developing non-gel creams, foams, sprays, or combination products.

A generic applicant has several potential strategies:

Strategy	Patent exposure
Copy the reference gel, including titanium dioxide	High exposure
Use brimonidine without titanium dioxide	Lower literal exposure
Use a carrier outside the listed categories	Potentially lower exposure, subject to characterization
Use a different active ingredient	Outside the brimonidine claims
Use a different facial-erythema mechanism	Outside the composition claims
Use a titanium-dioxide-free gel with alternative opacifier	Potential design-around
Use a different package while retaining the formulation	Composition claims remain relevant

Changing the container alone is not a reliable design-around because claims 1, 17, 20, and 21 independently cover the composition. Conversely, removing titanium dioxide can eliminate a required limitation from all issued independent claims identified here, although equivalence and other patent families must be evaluated separately.

What Paragraph IV risks exist for a brimonidine generic?

A Paragraph IV challenge would likely focus on four issues:

Written description and enablement

The challenger could argue that the claims are broader than the disclosure, particularly across numerous carrier types and formulation combinations. The patent’s detailed dependent claims provide narrower embodiments that may be more resistant to a broad written-description attack.

Anticipation

Prior art would need to disclose every limitation of the challenged claim, including brimonidine, titanium dioxide, the relevant carrier, and any facial or non-ophthalmic restriction. A reference disclosing brimonidine gel without titanium dioxide would not anticipate the claims as written.

Obviousness

The principal obviousness theory would combine known topical brimonidine formulations with titanium dioxide as an opacifier, pigment, or formulation excipient. The patent owner would likely rely on formulation performance, stability, tolerability, appearance, and facial-erythema results to defend nonobviousness.

Infringement

A proposed product that contains brimonidine tartrate, titanium dioxide, and an aqueous carbomer gel at a pH of 5 to 8 presents the clearest literal infringement risk. A formulation omitting titanium dioxide or using a materially different delivery form has a stronger noninfringement position.

What patent litigation and settlement issues affect the patent?

A complete litigation determination requires review of PACER, district-court dockets, PTAB proceedings, FDA Paragraph IV notices, and any settlement agreements. The patent itself does not establish whether a particular generic applicant has been sued, settled, licensed, or authorized for an early launch.

For commercial diligence, the relevant events are:

Paragraph IV notice to the NDA holder or patent owner.
A 45-day patent-infringement filing window.
Any 30-month ANDA approval stay.
Claim-construction rulings.
Summary judgment on infringement or validity.
Trial judgment and appeal.
Settlement terms governing launch date.
Authorized-generic or license arrangements.

No biosimilar litigation pathway applies to this patent. Any challenge would proceed through the small-molecule ANDA and Hatch-Waxman framework.

How strong is the patent estate around brimonidine topical products?

US 8,231,885 is strongest against a close copy of a titanium-dioxide-containing brimonidine gel or cream. Its strengths are:

Multiple independent composition claims.
Separate container claims.
Facial and non-ophthalmic claim versions.
Dependent claims covering concentration, pH, preservatives, humectants, gelling agents, and cream components.
Direct relevance to a commercial dermatology dosage form.

Its limitations are equally material:

Titanium dioxide is required in every independent claim.
The claims are limited to listed topical carrier categories.
The patent does not claim brimonidine generally.
The identified claims do not independently claim a treatment method.
A formulation design-around may be possible through excipient substitution or dosage-form selection.

The patent should therefore be characterized as a targeted formulation barrier, not a compound or platform patent.

What geographic coverage does US 8,231,885 provide?

The patent provides protection only in the United States. Parallel protection must be assessed through related applications and national-stage filings in jurisdictions such as Europe, Canada, Japan, Australia, and China. A US patent does not block manufacture, sale, or use outside the United States.

International risk depends on whether corresponding claims require:

Brimonidine and titanium dioxide.
A facial topical composition.
A gel, cream, or other listed carrier.
A specified concentration or pH.
A container or delivery system.

Manufacturing outside the United States can still create US exposure if the patented formulation is imported, sold, offered for sale, or used in the United States.

Key Takeaways

US 8,231,885 is a formulation and packaging patent for topical brimonidine products.
Titanium dioxide is a required element of every independent claim identified.
Brimonidine without titanium dioxide is outside the literal scope of those claims.
The strongest risk profile is a facial, non-ophthalmic brimonidine gel containing titanium dioxide.
Claims 3-9 and 10-16 add commercially relevant gel and cream limitations.
Claims 18, 19, and 22 create separate container-based exposure.
Mirvaso’s brimonidine tartrate gel is closely aligned with the claimed product category.
The nominal patent term is expected to extend to approximately November 2030, subject to official term adjustments and Orange Book data.
Generic applicants may use Paragraph IV, Paragraph III, or formulation design-around strategies.
No biosimilar pathway applies because brimonidine is a small-molecule drug.
The patent is a targeted formulation barrier rather than a broad brimonidine compound patent.

FAQs About US Patent 8,231,885

Does US 8,231,885 cover brimonidine ophthalmic drops?

No. The identified claims are directed to topical dermal formulations and, in claims 20-22, expressly limited to facial and non-ophthalmic application.

Can a generic brimonidine gel avoid the patent by removing titanium dioxide?

Removing titanium dioxide addresses a required limitation of every independent claim identified. The generic would still need to assess other patents, regulatory requirements, formulation equivalence, and any doctrine-of-equivalents argument.

Does the patent cover a brimonidine cream?

Yes. Claims 10-16 expressly cover cream formulations, with dependent claims addressing concentration, pH, preservatives, local anesthetics, humectants, and specified cream ingredients.

Is a squeeze tube required for infringement?

No. The container claims identify squeeze bottles or tubes in claim 19, but the composition claims can apply regardless of packaging.

Is US 8,231,885 a method-of-use patent for rosacea?

The claims provided are composition and container claims, not method-of-use claims. The patent’s commercial relevance to rosacea arises from the facial topical product category rather than an express treatment-method limitation.

References

United States Patent and Trademark Office. (2012). Topical compositions containing brimonidine, U.S. Patent No. 8,231,885.
U.S. Food and Drug Administration. (2013). Mirvaso (brimonidine tartrate) topical gel, 0.33% prescribing information.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application approvals and patent certifications under the Hatch-Waxman Act.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1631293	⤷ Start Trial	CR 2014 00031	Denmark	⤷ Start Trial
European Patent Office	1631293	⤷ Start Trial	C300683	Netherlands	⤷ Start Trial
European Patent Office	1631293	⤷ Start Trial	1490049-2	Sweden	⤷ Start Trial
European Patent Office	1631293	⤷ Start Trial	C20140022 00150	Estonia	⤷ Start Trial
European Patent Office	1631293	⤷ Start Trial	92462	Luxembourg	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,231,885

Summary for Patent: 8,231,885